Lithium Ionic Corp.
Figure 1
Salinas and Itinga Project Location
Figure 2
Looks Good to Me-!
Black Bolt-
GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
Lithium Ionic Corp.
Figure 1
Salinas and Itinga Project Location
Figure 2
Looks Good to Me-!
Black Bolt-
Stoney how you doing? Market feels chunky? Janes following some of my pump trades(HUBC), lol! Yesterday I bought a few thou of Corbus in the $3s, out $6.00
TED-! janes already made a killing in that pages ago. she must of re bought.>
Think about SQ maybe They call it Block.
My goal 4 beers before lunch.
-Your portfolio advisor
-Your portfolio advisor
Selling the $255 puts, trying for above $.65. That banking Index is a sore thumb.
Stoney, why has CRBP been going up? Flat on all calls and puts.
Dr- Hey stoney tell me how you blew your hamstring out.
-: Well, it was St Patty's day and I was getting off a barstool...
I swear getting old folks, don't do it. I went to the bar walking normal.I return with a huge limp.
My hamstring is completely in a knot.
-: Well, it was St Patty's day and I was getting off a barstool...
I swear getting old folks, don't do it. I went to the bar walking normal.I return with a huge limp.
My hamstring is completely in a knot.
This co has been quiet for along time.
Searches are very high on this name which means robin Hood is involved.
Corbus Pharmaceuticals' CRB-601 shows tumor growth inhibition 11/10/22 CRBP Corbus Pharmaceuticals is presenting new preclinical data for CRB-601 in a poster presentation at the Society for Immunotherapy of Cancer Annual Meeting in Boston. The latest preclinical data demonstrate "significant tumor growth inhibition" by CRB-601 as a single agent and in combination with anti-PD-1 treatment. In addition, treatment with CRB-601 appears to restore sensitivity to checkpoint inhibitors in the Pan02 and 4T1 syngeneic tumor models, regarded as "desert" tumors that are non-responsive to current CPIs. Collectively these data suggest that treatment with CRB-601 could address tumors with an immune excluded phenotype, as represented by this model, and facilitate sensitization to anti-PD-1 therapy. "CRB-601 demonstrates robust pre-clinical anti-tumor activity alone and in combination with anti-PD-1 therapy in tumors exhibiting a range of sensitivities to anti-PD-1 therapy. The ability of CRB-601 to significantly reduce the growth of tumors that are non-responsive to CPIs and to sensitize these tumors to CPI therapy continues to support our hypothesis that effective blockade of latent TGFbeta activation should lead to enhanced immune cell invasion in the tumor microenvironment and augment the effects of anti-PD-1 therapy. The increased activity of CRB-601 in tumors expressing alphavbeta8 provides a promising biomarker for patient selection and stratification," commented Rachael Brake, Chief Scientific Officer. Corbus is currently developing CRB-601 as a potential treatment for solid tumor cancers, and the program is on schedule for an IND submission in mid-2023.
Mid 2023 is basically now..... Watch OBV.> (On balance volume)